These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34100299)

  • 1. Gender-dependent association of
    Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
    Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
    [No Abstract]   [Full Text] [Related]  

  • 2. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
    Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.
    Romiti A; Roberto M; D'Antonio C; Onesti CE; Barucca V; Milano A; Gentile G; Lionetto L; Medda E; Mazzuca F; Botticelli A; Falcone R; Simmaco M; Marchetti P
    Anticancer Drugs; 2016 Nov; 27(10):1044-9. PubMed ID: 27557140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
    Shahrokni A; Rajebi MR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):231-4. PubMed ID: 19822515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
    Chao YL; Anders CK
    Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
    [No Abstract]   [Full Text] [Related]  

  • 11. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
    Castro-Rojas CA; Esparza-Mota AR; Hernandez-Cabrera F; Romero-Diaz VJ; Gonzalez-Guerrero JF; Maldonado-Garza H; Garcia-Gonzalez IS; Buenaventura-Cisneros S; Sanchez-Lopez JY; Ortiz-Lopez R; Camacho-Morales A; Barboza-Quintana O; Rojas-Martinez A
    Drug Metab Pers Ther; 2017 Dec; 32(4):209-218. PubMed ID: 29257755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.
    Meulendijks D; Jacobs BA; Aliev A; Pluim D; van Werkhoven E; Deenen MJ; Beijnen JH; Cats A; Schellens JH
    Int J Cancer; 2016 Jan; 138(1):245-53. PubMed ID: 26189437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
    Saif MW
    Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of the most common polymorphisms in TYMS gene in Slavic population of central Europe.
    Pastorakova A; Chandogova D; Chandoga J; Luha J; Bohmer D; Malova J; Braxatorisova T; Juhosova M; Reznakova S; Petrovic R
    Neoplasma; 2017; 64(6):962-970. PubMed ID: 28895423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidylate synthase pharmacogenetics.
    Marsh S
    Invest New Drugs; 2005 Dec; 23(6):533-7. PubMed ID: 16267625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
    Rosmarin D; Palles C; Church D; Domingo E; Jones A; Johnstone E; Wang H; Love S; Julier P; Scudder C; Nicholson G; Gonzalez-Neira A; Martin M; Sargent D; Green E; McLeod H; Zanger UM; Schwab M; Braun M; Seymour M; Thompson L; Lacas B; Boige V; Ribelles N; Afzal S; Enghusen H; Jensen SA; Etienne-Grimaldi MC; Milano G; Wadelius M; Glimelius B; Garmo H; Gusella M; Lecomte T; Laurent-Puig P; Martinez-Balibrea E; Sharma R; Garcia-Foncillas J; Kleibl Z; Morel A; Pignon JP; Midgley R; Kerr D; Tomlinson I
    J Clin Oncol; 2014 Apr; 32(10):1031-9. PubMed ID: 24590654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.